1. National Cancer Information Center. Annual report of cancer statistics in Korea in 2021. Goyang: National Cancer Center, 2023. 2. Health Insurance Review & Assessment Service. Results of the 2nd adequacy evaluation for lung cancer 2015 [Internet]. Wonju (KR): Health Insurance Review & Assessment Service, c2025 [cited year mon day]. Available from: https://www.hira.or.kr/cms/open/04/04/12/2015_10.pdf. 3. Health Insurance Review & Assessment Service. Results of the 5th adequacy evaluation for lung cancer 2020 [Internet]. Wonju (KR): Health Insurance Review & Assessment Service, c2025 [cited year mon day]. Available from: https://www.hira.or.kr/cms/open/04/04/12/2020_14.pdf. 4. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395–409.

5. Jang SH. Korean National Lung Cancer Screening. Korean J Med 2020;95:95–103.

6. Jang SH, Sheen S, Kim HY, et al. The Korean guideline for lung cancer screening. J Korean Med Assoc 2015;58:291–301. 7. Lee J, Lim J, Kim Y, et al. Development of protocol for Korean Lung Cancer Screening Project (K-LUCAS) to evaluate effectiveness and feasibility to implement national cancer screening program. Cancer Res Treat 2019;51:1285–1294.

8. Kim W, Lee SC, Lee WR, Chun S. The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea. Lung Cancer 2023;186:107412.

9. Hardavella G, Frille A, Sreter KB, et al. Lung cancer screening: where do we stand? Breathe (Sheff) 2024;20:230190.

10. Lee S, Park EH, Jang BY, et al. Survival of lung cancer patients according to screening eligibility using Korean Lung Cancer Registry 2014-2016. Sci Rep 2024;14:22585.

11. Lee J, Kim Y, Kim HY, et al. Feasibility of implementing a national lung cancer screening program: interim results from the Korean Lung Cancer Screening Project (K-LUCAS). Transl Lung Cancer Res 2021;10:723–736.

12. Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev 2012;21:308–315.

13. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019;30:1162–1169.

14. Salfity HVN, Tong BC, Kocher MR, Tailor TD. Historical perspective on lung cancer screening. Thorac Surg Clin 2023;33:309–321.

15. Adams SJ, Stone E, Baldwin DR, Vliegenthart R, Lee P, Fintelmann FJ. Lung cancer screening. Lancet 2023;401:390–408.

16. Henschke CI, McCauley DI, Yankelevitz DF, et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet 1999;354:99–105.

17. Reck M, Dettmer S, Kauczor HU, Kaaks R, Reinmuth N, Vogel-Claussen J. Lung cancer screening with low-dose computed tomography. Dtsch Arztebl Int 2023;120:387–392.

18. Gohagan J, Marcus P, Fagerstrom R, Pinsky P, Kramer B, Prorok P, Writing Committee, Lung Screening Study Research Group. Baseline findings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004;126:114–121.

19. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med 2020;382:503–513.

20. Infante M, Cavuto S, Lutman FR, et al.; DANTE Study Group. Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med 2015;191:1166–1175.

21. Blanchon T, Bréchot JM, Grenier PA, et al.; Dépiscan Group. Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer 2007;58:50–58.

22. Paci E, Puliti D, Lopes Pegna A, et al.; the ITALUNG Working Group. Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 2017;72:825–831.

23. Wille MM, Dirksen A, Ashraf H, et al. Results of the randomized danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med 2016;193:542–551.

24. Pastorino U, Silva M, Sestini S, et al. Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 2019;30:1672.

25. Becker N, Motsch E, Trotter A, et al. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial. Int J Cancer 2020;146:1503–1513.

26. Field JK, Vulkan D, Davies MPA, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur 2021;10:100179.

27. Connal S, Cameron JM, Sala A, et al. Liquid biopsies: the future of cancer early detection. J Transl Med 2023;21:118.

28. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol 2019;16:409–424.

29. Schult TA, Lauer MJ, Berker Y, et al. Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics. Proc Natl Acad Sci U S A 2021;118:e2110633118.

31. Klein EA, Richards D, Cohn A, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 2021;32:1167–1177.

32. Nadauld LD, McDonnell CH 3rd, Beer TM, et al. The PATHFINDER study: assessment of the implementation of an investigational multi-cancer early detection test into clinical practice. Cancers (Basel) 2021;13:3501.

33. Nicholson BD, Oke J, Virdee PS, et al. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study. Lancet Oncol 2023;24:733–743.

34. Neal RD, Johnson P, Clarke CA, et al. Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers (Basel) 2022;14:4818.

35. Dickson JL, Hall H, Horst C, et al.; SUMMIT consortium. Uptake of invitations to a lung health check offering low-dose CT lung cancer screening among an ethnically and socioeconomically diverse population at risk of lung cancer in the UK (SUMMIT): a prospective, longitudinal cohort study. Lancet Public Health 2023;8:e130–e140.

38. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 2018;359:926–930.

39. Lennon AM, Buchanan AH, Kinde I, et al. Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. Science 2020;369:eabb9601.

40. Chung DC, Gray DM 2nd, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med 2024;390:973–983.

41. Jamshidi A, Liu MC, Klein EA, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell 2022;40:1537–1549.e12.

42. Guardant Health, Inc. Screening for High Frequency Malignant Disease (SHIELD) [Internet]. National Library of Medicine, 2022 [last update posted 2025 Mar 13]. Available from: https://clinicaltrials.gov/study/NCT05117840. 43. Doubeni CA, Wilkinson JM, Korsen N, Midthun DE. Lung cancer screening guidelines implementation in primary care: a call to action. Ann Fam Med 2020;18:196–201.

44. Kim HC, Jung CY, Cho DG, et al. Clinical characteristics and prognostic factors of lung cancer in Korea: a pilot study of data from the Korean Nationwide Lung Cancer Registry. Tuberc Respir Dis (Seoul) 2019;82:118–125.

45. Abdayem P, Planchard D. Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer. Eur Respir Rev 2021;30:200294.

46. Zhang Y, Sun B, Yu Y, et al. Multimodal fusion of liquid biopsy and CT enhances differential diagnosis of early-stage lung adenocarcinoma. NPJ Precis Oncol 2024;8:50.